

Geoffrey Weiss

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1545761/geoffrey-weiss-publications-by-year.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

133
papers

11,774
citations

52
h-index

107
g-index

134
ext. papers

12,653
ext. citations

3.7
avg, IF

5.03
L-index

#	Paper	IF	Citations
133	Do Patients Regret Having Received Systemic Treatment for Advanced Non-Small Cell Lung Cancer: A Prospective Evaluation. <i>Oncologist</i> , 2021 , 26, 224-230	5.7	0
132	MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma 2020 , 8,		22
131	A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma. <i>Oncology</i> , 2018 , 94, 329-339	3.6	21
130	Understanding Advanced Prostate Cancer Decision Making Utilizing an Interactive Decision Aid. <i>Cancer Nursing</i> , 2018 , 41, 2-10	2.6	13
129	Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2028-2036	2.2	72
128	Melanoma NOS1 expression promotes dysfunctional IFN signaling. <i>Journal of Clinical Investigation</i> , 2014 , 124, 2147-59	15.9	30
127	A theory-based decision aid for patients with cancer: results of feasibility and acceptability testing of DecisionKEYS for cancer. <i>Supportive Care in Cancer</i> , 2013 , 21, 889-99	3.9	15
126	Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47). <i>Clinical Cancer Research</i> , 2013 , 19, 3611-20	12.9	31
125	Surgical management of the patient with metastatic melanoma to the heart. <i>Journal of Cardiac Surgery</i> , 2013 , 28, 124-8	1.3	4
124	Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. <i>Annals of Surgical Oncology</i> , 2011 , 18, 619-27	3.1	167
123	Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma. <i>Clinical Cancer Research</i> , 2011 , 17, 7440-50	12.9	68
122	Helical tomotherapy-based STAT RT: Dosimetric evaluation for clinical implementation of a rapid radiation palliation program. <i>Medical Dosimetry</i> , 2010 , 35, 280-6	1.3	7
121	Accelerated treatment using intensity-modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinoma. <i>Cancer</i> , 2009 , 115, 5117-25	6.4	53
120	Unresectable cholangiocarcinoma: comparison of survival in biliary stenting alone versus stenting with photodynamic therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2008 , 6, 290-7	6.9	132
119	Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study. <i>Clinical Cancer Research</i> , 2008 , 14, 7924-9	12.9	138
118	Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. <i>Cancer</i> , 2008 , 113, 2139-45	6.4	70
117	A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2007 , 59, 165-74	3.5	36

116	Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , 2006 , 12, 5207-15	12.9	55
115	Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712. <i>Journal of Clinical Oncology</i> , 2006 , 24, 5242-6	2.2	30
114	Locally advanced prostate cancer treated with concomitant radiation and 5-fluorouracil: Southwest Oncology Group Study 9024. <i>Journal of Urology</i> , 2006 , 176, 548-53; discussion 553	2.5	8
113	Tirapazamine plus cisplatin in advanced or recurrent carcinoma of the uterine cervix: a Southwest Oncology Group study. <i>International Journal of Gynecological Cancer</i> , 2006 , 16, 298-305	3.5	21
112	Phase II Trial of Paclitaxel, Carboplatin, and Topotecan with G-CSF Support in Previously Untreated Patients with Extensive Stage Small Cell Lung Cancer: Southwest Oncology Group 9914. <i>Journal of Thoracic Oncology</i> , 2006 , 1, 991-995	8.9	4
111	The modulation of prostate cancer risk with alpha-tocopherol: a pilot randomized, controlled clinical trial. <i>Journal of Urology</i> , 2005 , 174, 519-22	2.5	17
110	A phase II clinical trial of oral bropiramine in combination with intravesical bacillus Calmette-Guérin for carcinoma in situ of the bladder: a Southwest Oncology Group Study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2005 , 23, 386-9	2.8	8
109	Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 133-41 ^{2.2}	2.2	624
108	Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 1819-25	2.2	90
107	NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. <i>Annals of Oncology</i> , 2004 , 15, 885-90	10.3	90
106	Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. <i>Clinical Cancer Research</i> , 2004 , 10, 5022-6	12.9	44
105	Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713. <i>Journal of Clinical Oncology</i> , 2004 , 22, 127-32	2.2	34
104	A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms. <i>Clinical Cancer Research</i> , 2004 , 10, 1645-56	12.9	27
103	Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study. <i>Gynecologic Oncology</i> , 2004 , 95, 506-12	4.9	22
102	Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. <i>Journal of Clinical Oncology</i> , 2003 , 21, 3133-40	2.2	255
101	Phase 1 study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder. <i>Journal of Immunotherapy</i> , 2003 , 26, 343-8	5	58
100	Doegje-Potter syndrome: hypoglycemia associated with malignant solitary fibrous tumor. <i>Medical Oncology</i> , 2003 , 20, 403-8	3.7	37
99	Phase II trial of single agent carboplatin followed by dose-intense paclitaxel, followed by maintenance paclitaxel therapy in stage IV ovarian, fallopian tube, and peritoneal cancers: a Southwest Oncology Group trial. <i>Gynecologic Oncology</i> , 2003 , 88, 282-8	4.9	9

98	Current issues in the management of advanced squamous cell carcinoma of the penis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2003 , 21, 431-8	2.8	11
97	Management of locally advanced bladder cancer: early vs deferred chemotherapy. <i>World Journal of Urology</i> , 2002 , 20, 175-82	4	2
96	Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. <i>Journal of Cancer Research and Clinical Oncology</i> , 2002 , 128, 214-8	4.9	122
95	Troxacitabine, an L-Stereoisomeric Nucleoside Analog, on a Five-Times-Daily Schedule: A Phase I and Pharmacokinetic Study in Patients With Advanced Solid Malignancies. <i>Journal of Clinical Oncology</i> , 2002 , 20, 96-109	2.2	16
94	Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. <i>Journal of Clinical Oncology</i> , 2002 , 20, 2058-66	2.2	186
93	Phase II trial of recombinant human interleukin-4 in patients with advanced renal cell carcinoma: a southwest oncology group study. <i>Journal of Immunotherapy</i> , 2002 , 25, 352-8	5	38
92	Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326). <i>Gynecologic Oncology</i> , 2001 , 82, 317-22	4.9	30
91	Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel. <i>Journal of Clinical Oncology</i> , 2001 , 19, 2493-503	2.2	34
90	Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials. <i>Journal of Clinical Oncology</i> , 2001 , 19, 3194-202	2.2	55
89	Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. <i>Journal of Clinical Oncology</i> , 2001 , 19, 3210-8	2.2	963
88	Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties. <i>Journal of Clinical Oncology</i> , 2001 , 19, 2937-47	2.2	38
87	A phase II trial of topotecan in esophageal carcinoma: a Southwest Oncology Group study (SWOG 9339). <i>Investigational New Drugs</i> , 2000 , 18, 199-202	4.3	12
86	A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors. <i>Annals of Oncology</i> , 2000 , 11, 333-8	10.3	15
85	Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies. <i>Journal of Clinical Oncology</i> , 2000 , 18, 167-77	2.2	21
84	Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 1999 , 17, 1095-104	2.2	57
83	Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. <i>Journal of Clinical Oncology</i> , 1999 , 17, 2604-13	2.2	101
82	Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies. <i>Journal of Clinical Oncology</i> , 1999 , 17, 1915-25	2.2	67
81	Phase II trial of biochemotherapy with interferon alpha, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 1999 , 125, 292-6	4.9	11

80	High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. <i>Journal of Clinical Oncology</i> , 1999 , 17, 2105-16	2.2	1547
79	A phase I and pharmacokinetic trial of terephthalamidine (NSC 57155) as a 120-hour continuous infusion. <i>Investigational New Drugs</i> , 1998 , 16, 57-67	4.3	
78	Phase II trial of oral beta-all trans-retinoic acid in hepatocellular carcinoma (SWOG 9157). <i>Investigational New Drugs</i> , 1998 , 16, 171-3	4.3	16
77	13-cis-retinoic acid or all-trans-retinoic acid plus interferon-alpha in recurrent cervical cancer: a Southwest Oncology Group phase II randomized trial. <i>Gynecologic Oncology</i> , 1998 , 71, 386-90	4.9	33
76	Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors. <i>Annals of Oncology</i> , 1998 , 9, 733-8	10.3	64
75	Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. <i>Journal of Clinical Oncology</i> , 1998 , 16, 2459-65	2.2	473
74	Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study. <i>Journal of Clinical Oncology</i> , 1998 , 16, 664-9	2.2	52
73	A Bioavailability and Pharmacokinetic Study of Oral and Intravenous Hydroxyurea. <i>Blood</i> , 1998 , 91, 1533-1541	1	
72	Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma. <i>Annals of Oncology</i> , 1997 , 8, 1003-8	10.3	27
71	Pityriasis rubra pilaris as an initial presentation of hepatocellular carcinoma. <i>Dermatology</i> , 1997 , 194, 166-7	4.4	19
70	Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study. <i>Journal of Clinical Oncology</i> , 1997 , 15, 2414-9	2.2	71
69	Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. <i>Journal of Clinical Oncology</i> , 1996 , 14, 1128-35	2.2	293
68	A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium. <i>Annals of Oncology</i> , 1996 , 7, 491-6	10.3	36
67	A randomized phase I study of oral etoposide with or without granulocyte-macrophage colony-stimulating factor for the treatment of patients with advanced cancer. <i>Anti-Cancer Drugs</i> , 1996 , 7, 402-9	2.4	1
66	Vitiligo and Graves Disease following treatment of malignant melanoma with recombinant human interleukin 4. <i>Dermatology</i> , 1996 , 192, 283-5	4.4	8
65	Pharmacokinetic profile of Mitoguazone (MGBG) in patients with AIDS related non-Hodgkin's lymphoma. <i>Investigational New Drugs</i> , 1996 , 14, 227-34	4.3	9
64	Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. <i>Journal of Clinical Oncology</i> , 1995 , 13, 2895-9	2.2	76
63	Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. <i>Journal of Clinical Oncology</i> , 1995 , 13, 1303-11	2.2	286

62	Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study. <i>Journal of Clinical Oncology</i> , 1995 , 13, 2924-30	2.2	68
61	A phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 1995 , 35, 397-402	3.5	11
60	Phase II trial of CHIP for the treatment of advanced, hormonally refractory carcinoma of the prostate. A Southwest Oncology Group Study. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1995 , 18, 400-2	2.7	4
59	Deoxyspergualin. <i>Anti-Cancer Drugs</i> , 1995 , 6, 229-236	2.4	10
58	A phase II study of the continuous intravenous infusion of interleukin-6 for metastatic renal cell carcinoma. <i>Journal of Immunotherapy</i> , 1995 , 18, 52-6	5	17
57	A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study. <i>Cancer</i> , 1995 , 75, 815-20	6.4	129
56	A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas. A Southwest Oncology Group study. <i>Cancer</i> , 1995 , 76, 2248-52	6.4	59
55	Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. <i>Journal of Clinical Oncology</i> , 1994 , 12, 1553-60	2.2	117
54	A phase II clinical trial of interleukin-2 and lymphokine-activated killer cells in advanced colorectal carcinoma. <i>Journal of Immunotherapy</i> , 1994 , 15, 74-8	5	29
53	Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma. <i>Journal of Immunotherapy</i> , 1994 , 15, 147-53	5	52
52	A phase II trial of DaunoXome, liposome-encapsulated daunorubicin, in patients with metastatic adenocarcinoma of the colon. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1994 , 17, 498-501	2.7	28
51	Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors. <i>Journal of Immunotherapy</i> , 1994 , 16, 216-23	5	22
50	Phase I clinical trial of ormaplatin (tetraplatin, NSC 363812). <i>Anti-Cancer Drugs</i> , 1994 , 5, 520-6	2.4	31
49	Phase I and pharmacokinetic trial of weekly CPT-11. <i>Journal of Clinical Oncology</i> , 1993 , 11, 2194-204	2.2	245
48	Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 1993 , 11, 661-70	2.2	164
47	Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects. <i>Journal of Clinical Oncology</i> , 1993 , 11, 1496-505	2.2	40
46	Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. <i>Journal of Clinical Oncology</i> , 1993 , 11, 1969-77	2.2	156
45	Salmonella arizonae peritonitis secondary to ingestion of rattlesnake capsules for gastric cancer. <i>Journal of Clinical Oncology</i> , 1993 , 11, 2288-9	2.2	7

44	An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. <i>Journal of Clinical Oncology</i> , 1993 , 11, 1276-85	2.2	372
43	Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. <i>Journal of Clinical Oncology</i> , 1993 , 11, 873-8	2.2	127
42	Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion. <i>Journal of Clinical Oncology</i> , 1993 , 11, 950-8	2.2	119
41	A phase I clinical and pharmacokinetic study of the oral and the oral/intravenous administration of menogaril. <i>Investigational New Drugs</i> , 1993 , 11, 17-27	4.3	3
40	Phase II trial of 6-thioguanine administered as 120 hour continuous infusion for refractory or recurrent small cell lung cancer. A Southwest Oncology Group study. <i>Investigational New Drugs</i> , 1993 , 11, 81-3	4.3	3
39	A phase II trial of piroxantrone in adenocarcinoma of the pancreas. A Southwest Oncology Group study. <i>Investigational New Drugs</i> , 1993 , 11, 329-31	4.3	10
38	A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. <i>Anti-Cancer Drugs</i> , 1992 , 3, 337-45	2.4	81
37	Phase II study of platinum and mitoxantrone in metastatic prostate cancer: a Southwest Oncology Group Study. <i>European Journal of Cancer</i> , 1992 , 28, 477-8	7.5	18
36	A randomized phase II trial of trimetrexate or didemnin B for the treatment of metastatic or recurrent squamous carcinoma of the uterine cervix: a Southwest Oncology Group trial. <i>Gynecologic Oncology</i> , 1992 , 45, 303-6	4.9	21
35	Malignant melanoma in a Hispanic male with nevus of Ota. <i>Dermatology</i> , 1992 , 185, 146-50	4.4	20
34	Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. <i>Journal of Clinical Oncology</i> , 1992 , 10, 881-9	2.2	205
33	A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 1992 , 10, 275-81	2.2	123
32	Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. <i>Investigational New Drugs</i> , 1992 , 10, 239-53	4.3	517
31	Phase II trial of didemnin-B in advanced epithelial ovarian cancer. A Southwest Oncology Group study. <i>Investigational New Drugs</i> , 1992 , 10, 23-4	4.3	17
30	Phase I evaluation of 773U82.HCl, a member of a new class of DNA intercalators. <i>Anti-Cancer Drugs</i> , 1991 , 2, 357-63	2.4	1
29	Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphoma. <i>Journal of Immunotherapy</i> , 1991 , 10, 214-20	5	23
28	Phase I clinical and pharmacokinetic trial of flavone acetic acid. <i>Journal of the National Cancer Institute</i> , 1991 , 83, 124-8	9.7	22
27	Phase I evaluation of crisnatol (BWA770U mesylate) on a monthly extended infusion schedule. <i>Selective Cancer Therapeutics</i> , 1991 , 7, 85-91		1

26	Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. <i>Journal of the National Cancer Institute</i> , 1991 , 83, 926-32	9.7	121
25	Second-line treatment of advanced measurable ovarian cancer with iproplatin: a Southwest Oncology Group study. <i>European Journal of Cancer & Clinical Oncology</i> , 1991 , 27, 135-8		19
24	A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma. <i>Journal of Clinical Oncology</i> , 1991 , 9, 641-8	2.2	94
23	A phase I trial of taxol given by a 6-hour intravenous infusion. <i>Journal of Clinical Oncology</i> , 1991 , 9, 1261-72		149
22	Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen. <i>Journal of Clinical Oncology</i> , 1990 , 8, 1630-6	2.2	75
21	Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells. <i>Journal of Clinical Oncology</i> , 1990 , 8, 1138-47	2.2	73
20	An outbreak of hepatitis A among cancer patients treated with interleukin-2 and lymphokine-activated killer cells. <i>Journal of Infectious Diseases</i> , 1990 , 161, 647-52	7	29
19	Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma. <i>Journal of the National Cancer Institute</i> , 1990 , 82, 1397-402	9.7	39
18	A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group study. <i>Gynecologic Oncology</i> , 1990 , 39, 332-6	4.9	56
17	A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: a Southwest Oncology Group trial. <i>Gynecologic Oncology</i> , 1990 , 37, 354-8	4.9	28
16	Phase I clinical investigation of amonafide. <i>Journal of Clinical Oncology</i> , 1989 , 7, 1351-8	2.2	36
15	Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. <i>Journal of Clinical Oncology</i> , 1989 , 7, 486-98	2.2	293
14	A phase I clinical and pharmacological study of weekly intravenous infusions of piritrexim (BW301U). <i>European Journal of Cancer & Clinical Oncology</i> , 1989 , 25, 1867-73		9
13	Review of interleukin-2 alone and interleukin-2/LAK clinical trials in metastatic malignant melanoma. <i>Cancer Treatment Reviews</i> , 1989 , 16 Suppl A, 29-38	14.4	19
12	Phase I trial of echinomycin (NSC 526417), a bifunctional intercalating agent, administered by 24-hour continuous infusion. <i>European Journal of Cancer & Clinical Oncology</i> , 1989 , 25, 797-803		11
11	A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. <i>Journal of Clinical Oncology</i> , 1989 , 7, 477-85	2.2	207
10	Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. <i>Annals of Internal Medicine</i> , 1988 , 108, 518-23	8	277
9	Second-Line Chemotherapy for Ovarian Cancer. <i>Clinical Obstetrics and Gynecology</i> , 1986 , 29, 665-677	1.7	4

8	Use of in vitro dose response effects to select antineoplastics for high-dose or regional administration regimens. <i>Journal of Clinical Oncology</i> , 1986 , 4, 1827-34	2.2	77
7	A phase I and pharmacokinetic comparison of hepatic arterial and peripheral vein infusions of bisantrene for liver cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1985 , 15, 144-8	3.5	1
6	Pulmonary uptake of technetium 99m macroaggregated albumin: a predictor of gastrointestinal toxicity during hepatic artery perfusion. <i>Journal of Clinical Oncology</i> , 1984 , 2, 1266-9	2.2	25
5	Phase-I trial of combination therapy with continuous-infusion MMRP and continuous-infusion 5-FU. <i>Cancer Chemotherapy and Pharmacology</i> , 1984 , 13, 136-8	3.5	6
4	Long-term hepatic arterial infusion of 5-fluorodeoxyuridine for liver metastases using an implantable infusion pump. <i>Journal of Clinical Oncology</i> , 1983 , 1, 337-44	2.2	123
3	A phase I trial of combination therapy with continuous-infusion PALA and continuous-infusion 5-FU. <i>Cancer Chemotherapy and Pharmacology</i> , 1982 , 8, 301-4	3.5	5
2	Testicular cancer in a Russell-Silver dwarf. <i>Journal of Urology</i> , 1981 , 126, 836-7	2.5	16
1	Reduction of some halocyclopropanes with sodium naphthalenide. <i>Journal of Organic Chemistry</i> , 1971 , 36, 2186-2188	4.2	7